The biopharmaceutical trade had a constructive yr in 2024, with weight problems drug builders persevering with to witness success. 19 of the highest 20 publicly traded world biopharmaceutical corporations reported income development, leading to a greater than 7.9% improve in complete income, as much as $880.4bn from 2023 to 2024, in accordance with GlobalData, a number one knowledge and analytics firm.
Eli Lilly skilled the best income development of 32% to $45bn in 2024, adopted by Novo Nordisk with 25.5% to $42.1bn. This income development was fuelled by the sturdy successes of the businesses’ weight problems and diabetes blockbuster medicine. Eli Lilly’s Mounjaro (tirzepatide) and Zepbound (tirzepatide) generated complete world gross sales of $16.5 billion in 2024, whereas Novo Nordisk’s Ozempic (semaglutide) and Wegovy (semaglutide) amassed mixed world gross sales of $25.9bn. Eli Lilly’s income development was additional pushed by its breast most cancers drug Verzenio (abemaciclib), which recorded world gross sales of $5.3bn in 2024. The income development hole between the 2 corporations is anticipated to widen as Eli Lilly’s Mounjaro and Zepbound proceed to seize long-term market share from Novo Nordisk’s Ozempic and Wegovy. Eli Lilly is projected to see 34.3% income development to $59.2bn in 2025, whereas Novo Nordisk’s is just forecast to see 16.4% income development to $47.7bn in 2025, in accordance with GlobalData’s Gross sales and Forecast database.
Astellas Pharma additionally demonstrated sturdy efficiency with 19.2% development to $13.2bn, pushed by the gross sales of Xtandi (enzalutamide) for prostate most cancers, which registered world gross sales of $5.98bn in 2024.
Pfizer and Roche each witnessed a restoration in income after gross sales declines within the earlier yr, pushed by waning demand for his or her Covid-19 merchandise. Pfizer’s income grew 6.8% to $63.6bn in 2024, and Roche’s income grew 3% to $68.7bn in the identical yr. Pfizer’s Covid-19 antiviral therapy Paxlovid (nirmatrelvir and ritonavir) noticed an unprecedented 347% resurgence in gross sales to $5.7bn in 2024, spurred by sturdy demand within the US. Nevertheless, Pfizer’s post-pandemic gross sales restoration is more and more shifting in the direction of its non-Covid-19 merchandise, led by Eliquis (apixaban), which generated $13.3bn of world gross sales in 2024. The corporate is poised to see additional income development from its December 2023 acquisition of Seagen, with its marketed medicine Padcev (enfortumab vedotin), Adcetris (brentuximab vedotin), Tukysa (tucatinib), Tivdak (tisotumab vedotin) and Aidexi (disitamab vedotin) projected to realize mixed world gross sales of $8.8bn by 2031.
10 of the highest 20 corporations recorded above 10% year-on-year (YoY) development of their working revenue in 2024: Pfizer (1,134.1%), Merck & Co (1,017.1%), Eli Lilly (99.7%) and Astellas Pharma (52.5%) reported greater than 50% development. Pfizer’s huge improve in its working revenue was attributed to ongoing cost-cutting initiatives which saved $4.5bn. In the meantime, the sturdy success of Merck & Co’s Keytruda (pembrolizumab) led to a surge in its working revenue development of 1,017.1%. It was additional enhanced by decrease royalty charges and decreased analysis and growth (R&D) bills. Nevertheless, Bristol Myers Squibb (-171.7%), Bayer (-111.6%), and Gilead Sciences (-78.1%) reported greater than a 50% decline of their working revenue.
